Pfizer’s Covid Vaccine Trial May Beat Rivals to Early Look (1)

Sept. 22, 2020, 12:52 PM

The Covid-19 vaccine trial designed by Pfizer Inc. and its German partner BioNTech SE may allow them to find whether their shot works before their fastest-moving rivals.

The companies plan a first look after a mere 32 coronavirus infections have accumulated in their massive 44,000-person trial. That case total could be reached as soon as Sept. 27, according to Airfinity Ltd., a London-based analytics firms tracking vaccine trials.

Pfizer has also given itself four chances to get a preliminary result, before reaching the final goal of 164. Some trial experts say the company appears to be looking for a leg ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.